JPMorgan lifts target for Charles River Laboratories stock to USD 345.00
Published on 10/15/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and company metrics
- JPMorgan set a USD 345.00 target for Charles River Laboratories on October 14, 2026.
- Second-quarter revenue fell 2.7 percent to USD 1.00 billion.
- Charles River Laboratories stock costs EUR 275.40 at Lang & Schwarz on October 15, 2026 at 9:36 p.m. CEST, 0.18 percent above the Tradegate close of October 14, 2026.
- Market capitalization stood at USD 14.8 billion as of October 15, 2026.
JPMorgan raised its price target for Charles River Laboratories from USD 310.00 to USD 345.00 on October 14, 2026, putting the target 11.99 percent above the USD 308.05 home-market price. Moomoo carried the MT Newswires report. Charles River Laboratories stock was at EUR 275.40 at Lang & Schwarz on October 15, 2026 at 9:36 p.m. CEST, 0.18 percent above the Tradegate close of October 14, 2026 at EUR 274.90.
Quarterly revenue sets the backdrop
Charles River reported second-quarter 2026 revenue of USD 1.00 billion, down 2.7 percent from USD 1.03 billion in the second quarter of 2025. The company also reported a GAAP loss of USD 0.03 per diluted share, compared with GAAP earnings of USD 1.06 in the year-earlier quarter. The loss included a USD 63.7 million charge tied to divestitures. Charles River Laboratories reported the figures in its August 5, 2026 release.
Price position and trading range
The USD 308.05 NYSE price was 2.00 percent above the previous close on October 15, 2026. The session ranged from USD 295.33 to USD 309.48, while volume reached 612,350 shares against an average of 945,343. The 52-week range was USD 146.20 to USD 333.30, leaving the stock 7.50 percent below its high and 110.71 percent above its low.
Valuation and next reporting date
Charles River Laboratories had a market capitalization of USD 14.8 billion and a negative trailing price-to-earnings ratio on October 15, 2026, so the ratio does not provide a meaningful earnings comparison. The next earnings conference call is scheduled for November 4, 2026, at 9:00 a.m. Eastern Time, according to Charles River Laboratories.
Comparison with peers
Charles River Laboratories: plus 0.18 percent, market capitalization USD 14.8 billion.
ICON Public: plus 4.30 percent, P/E 41.41, market capitalization USD 13.6 billion.
Medpace: plus 2.51 percent, P/E 37.04, market capitalization USD 17.6 billion.
Trading levels remain close to the upper range
The euro quotation remains below the upper end of the German trading range reported for October 14, 2026, while the NYSE quotation sits 7.50 percent below its 52-week high. The contrast between the target of USD 345.00 and the current USD 308.05 price gives the analyst revision its main numerical significance.
The further course of trading is shown by the continuously updated real-time quote of Charles River Laboratories stock.
Charles River Laboratories market data
- Company: Charles River Laboratories International, Inc.
- ISIN: US1598641074
- Ticker: CRL
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 15, 2026, 9:36 p.m. CEST): EUR 275.40
- Change versus Tradegate close: plus 0.18 percent
- Tradegate close (October 14, 2026): EUR 274.90
- Market capitalization: USD 14.8 billion (as of October 15, 2026)
- 52-week range: USD 146.20-333.30 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
Market context: Market report S&P 500.
